BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BVXV shares.
View BVXV analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month target prices for BiondVax Pharmaceuticals' shares. Their BVXV share price forecasts range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 613.6% from the stock's current price.
View analysts price targets for BVXV or view top-rated stocks among Wall Street analysts.

BiondVax Pharmaceuticals' stock was trading at $23.50 at the beginning of the year. Since then, BVXV stock has decreased by 58.3% and is now trading at $9.81.
View the best growth stocks for 2022 here.

BiondVax Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 32,700 shares, a decrease of 86.9% from the October 31st total of 250,400 shares. Based on an average daily volume of 7,700 shares, the days-to-cover ratio is currently 4.2 days. Currently, 1.8% of the shares of the stock are short sold.
View BiondVax Pharmaceuticals' Short Interest.

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80.

Shares of BiondVax Pharmaceuticals reverse split on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

BiondVax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.55%).

Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BVXV stock can currently be purchased for approximately $9.81.

BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $14.06 million. The company earns $-12,850,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531.